Drugs Made In America Acquisition II Corp. 8-K

What Happened
Drugs Made In America Acquisition II Corp. announced on March 11, 2026 that it issued an unsecured convertible promissory note (the “Bridge Note”) to Alpha Multi Family Office for $150,000. The Bridge Loan is an initial tranche toward a contemplated $1,400,000 convertible notes financing described in a Letter of Intent. The note matures nine months from issuance, does not accrue interest, and may be converted or credited into the definitive financing documents earlier.

Key Details

• Issuer: Drugs Made In America Acquisition II Corp.; Investor: Alpha Multi Family Office.
• Amount: $150,000 Bridge Note issued March 11, 2026 toward a contemplated $1,400,000 financing.
• Terms: nine-month maturity, no interest, convertible at the investor’s option upon completion of the company’s initial business combination.
• Conversion: if converted at closing of the business combination, conversion price equals a 35% discount to the market price of the combined entity’s shares at conversion time.
• Use of proceeds: accounting, audit and other expenses related to the planned business combination.

Why It Matters
This creates a near-term financial obligation and provides immediate cash to cover transaction-related costs as the company pursues its business combination. The investor’s option to convert at a 35% discount could dilute existing shareholders if converted at closing. The note is unsecured and interest-free, so it is a relatively low-cost short-term funding source, but conversion terms and the contemplated larger financing increase potential share issuance tied to the transaction. Exhibits to the filing include the LOI, addendum and the Bridge Note.